Multi-agonist therapies targeting combinations of gut hormone receptors—such as GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors—represent a novel approach to enhancing metabolic outcomes in obesity treatment. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.